Endo, Vernalis Seek First Triptan Menstrual Migraine Indication With Frova sNDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Frovatriptan sNDA is supported by data from four studies, including two Phase III trials evaluating efficacy in short-term prevention of MM.